These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L; J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027 [TBL] [Abstract][Full Text] [Related]
3. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963 [TBL] [Abstract][Full Text] [Related]
4. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. Luis Jiménez J; Resino S; Martinez-Colom A; Bellón JM; Angeles Muñoz-Fernández M; J Antimicrob Chemother; 2005 Dec; 56(6):1081-6. PubMed ID: 16195257 [TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways? Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502 [TBL] [Abstract][Full Text] [Related]
8. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018 [TBL] [Abstract][Full Text] [Related]
9. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247 [TBL] [Abstract][Full Text] [Related]
10. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber TJ; Harrison L; Asboe D; Williams I; Kirk S; Gilson R; Bansi L; Pillay D; Dunn D; J Antimicrob Chemother; 2012 Apr; 67(4):995-1000. PubMed ID: 22258921 [TBL] [Abstract][Full Text] [Related]
11. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. Mo H; King MS; King K; Molla A; Brun S; Kempf DJ J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227 [TBL] [Abstract][Full Text] [Related]